Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 8:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 608 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Healthy Adult Participants Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

NCT01497431

View directory record Official record

Conditions: No Evidence of Disease, Prostate Carcinoma
Interventions: Selenium, Placebo, Laboratory Biomarker Analysis, Pharmacological Study, Methylselenocysteine; Dietary Supplement · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years to 80 Years · Male only

Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois • Buffalo, New York • Nashville, Tennessee

Source: ClinicalTrials.gov public record

Updated Nov 25, 2014 · Synced May 21, 2026, 8:48 PM EDT

Not yet recruiting Not applicable Interventional

Mystical Experiences Without Psychedelics and How Integration Improves Well-Being in Adults

NCT07584070

View directory record Official record

Conditions: Healthy Adult Participants
Interventions: Guided Invocation for Mystical Experience; Behavioral
Lead sponsor: Baylor University; Other
Eligibility: 18 Years and older

Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Waco, Texas

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

NCT04484337

View directory record Official record

Conditions: HIV Infections
Interventions: Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical non-steroidal anti-inflammatory drug, Topical steroid, Placebo creams/gels, Recombinant human hyaluronidase PH20 (rHuPH20); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years

Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more

Source: ClinicalTrials.gov public record

Updated Dec 3, 2023 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

NCT05797753

View directory record Official record

Conditions: Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions: SAR443820, Erythromycin ethyl succinate, Itraconazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Source: ClinicalTrials.gov public record

Updated Jan 2, 2025 · Synced May 21, 2026, 8:48 PM EDT

Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

NCT06899802

View directory record Official record

Conditions: Encephalitis
Interventions: MVA-BN-WEV, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 50 Years

Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Sacramento, California • Lilburn, Georgia • Lenexa, Kansas + 6 more

Source: ClinicalTrials.gov public record

Updated Sep 30, 2025 · Synced May 21, 2026, 8:48 PM EDT

Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

NCT06910839

View directory record Official record

Conditions: Overweight, Obesity
Interventions: PF-07976016, PF-06882961; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Anaheim, California

Source: ClinicalTrials.gov public record

Updated Aug 6, 2025 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

NCT04551586

View directory record Official record

Conditions: Healthy
Interventions: ACH-0145228: Immediate Release, ACH-0145228: Powder-in-capsule; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Source: ClinicalTrials.gov public record

Updated Dec 27, 2021 · Synced May 21, 2026, 8:48 PM EDT

Terminated Phase 2 Interventional

A Study of LY3549492 in Healthy Weight Adult Participants

NCT07085468

View directory record Official record

Conditions: Healthy
Interventions: LY3549492, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 80 Years

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 11
States / cities: Scottsdale, Arizona • Covina, California • Northridge, California + 8 more

Source: ClinicalTrials.gov public record

Updated Aug 28, 2025 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

TP-3654 Food Effect Study

NCT07492355

View directory record Official record

Conditions: Myelofibroses
Interventions: TP-3654; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Source: ClinicalTrials.gov public record

Updated Mar 24, 2026 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults

NCT01438606

View directory record Official record

Conditions: HIV Infections
Interventions: VSV-Indiana HIV gag vaccine, Placebo injection (normal saline); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years

Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 4
States / cities: San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more

Source: ClinicalTrials.gov public record

Updated Oct 14, 2021 · Synced May 21, 2026, 8:48 PM EDT

Recruiting No phase listed Observational Accepts healthy volunteers

CanCan Body Composition Study

NCT07305753

View directory record Official record

Conditions: Healthy Participants, Young Healthy Adults, Elderly (People Aged 65 or More)
Interventions: Not listed
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 90 Years

Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Source: ClinicalTrials.gov public record

Updated Dec 25, 2025 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants

NCT05796479

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Amlitelimab DP1, Amlitelimab DP2; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hialeah, Florida

Source: ClinicalTrials.gov public record

Updated Sep 18, 2025 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

NCT00091416

View directory record Official record

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years

Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2006
U.S. locations: 8
States / cities: Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more

Source: ClinicalTrials.gov public record

Updated Oct 13, 2021 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

NCT03928821

View directory record Official record

Conditions: HIV Infections
Interventions: PGT121, PGDM1400, 10-1074, VRC07-523LS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Nashville, Tennessee

Source: ClinicalTrials.gov public record

Updated Jul 10, 2022 · Synced May 21, 2026, 8:48 PM EDT

Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1

NCT07457736

View directory record Official record

Conditions: Healthy Adult Participants
Interventions: [ 18F]GATT-44; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New Haven, Connecticut

Source: ClinicalTrials.gov public record

Updated Apr 5, 2026 · Synced May 21, 2026, 8:48 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

NCT07549919

View directory record Official record

Conditions: Healthy Male Adults, Food Effect in Healthy Volunteers
Interventions: AJ201; Drug
Lead sponsor: AnnJi Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only

Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Source: ClinicalTrials.gov public record

Updated Apr 23, 2026 · Synced May 21, 2026, 8:48 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

NCT07511205

View directory record Official record

Conditions: Healthy Participants, Obesity
Interventions: AZD1043, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated Apr 26, 2026 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

NCT04827134

View directory record Official record

Conditions: HIV Infections
Interventions: TRIUMEQ, DOVATO; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years

Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Source: ClinicalTrials.gov public record

Updated Jun 4, 2023 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

NCT04696393

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Mitapivat tablet; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 64 Years

Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Source: ClinicalTrials.gov public record

Updated Apr 12, 2021 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

NCT07222878

View directory record Official record

Conditions: Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions: NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2); Drug
Lead sponsor: NeuroPro Therapeutics, Inc.; Industry
Eligibility: 19 Years to 65 Years

Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Source: ClinicalTrials.gov public record

Updated Apr 2, 2026 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

NCT06775730

View directory record Official record

Conditions: Healthy Adult Female Participants
Interventions: Ensitrelvir; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 35 Years · Female only

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Source: ClinicalTrials.gov public record

Updated May 3, 2025 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

NCT04194892

View directory record Official record

Conditions: Healthy
Interventions: Pegilodecakin; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Source: ClinicalTrials.gov public record

Updated Dec 10, 2019 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

NCT04350177

View directory record Official record

Conditions: Healthy Elderly, Parkinson Disease
Interventions: IkT-148009, Placebo; Drug
Lead sponsor: ABLi Therapeutics, Inc.; Industry
Eligibility: 55 Years to 70 Years

Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Long Beach, California • Hallandale, Florida • Farmington Hills, Michigan + 1 more

Source: ClinicalTrials.gov public record

Updated Mar 9, 2025 · Synced May 21, 2026, 8:48 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants

NCT05271799

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Gepotidacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Source: ClinicalTrials.gov public record

Updated Jan 29, 2023 · Synced May 21, 2026, 8:48 PM EDT